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Summary
While close contact between lymphokine-activated killer (LAK)/adherent, lymphokine-activated
killer (A-LAK) cells and tumor cells is believed to be a prerequisite for initiating the events leading
to tumor cell lysis, clear evidence for the ability of these effector cells to infiltrate tumors or
tumor metastases in vivo still has to be obtained. In the present study, we report that a significant
fraction of adoptively transferred A-LAK cells, labeled with fluorochromes for identification,
accumulates in lung and liver metastases of the B16 melanoma, theMCA 102 sarcoma and the
Lewis lung carcinoma lines . Thus, 5- to 10-fold higher numbers of A-LAK cells were found
in the malignant lesions compared to the surrounding normal tissue. The infiltration seemed
very heterogeneous after intravenous injection of moderate numbers ofA-LAK cells (15 x 106) .
However, after adoptive transfer of 45 million ALAK cells, an ALAK cell/tumor cell ratio
higher than 1:1 in most metastases was observed . Surprisingly, approximately 5% of the lung
metastases seemed totally resistant to infiltration even though neighboring metastases were highly
infiltrated .
While substantial infiltration of lung metastases was seen after i.v. injection, significant infiltration
ofliver metastases was seen only after intraportal injection of the A-LAK cells indicating impaired
traffic of intravenous injected A-LAK cells through the lung capillaries.
These results present direct evidence that A-LAK cells, upon a proper route of administration,
have the potential to migrate to and heavily infiltrate metastases from murine tumors of different
origin .
R
sults obtained from immunotherapy with IL-2 in com-
bination with lymphokine activated killer (LAK)'
cells have indicated dramatic reduction in the number of es-
tablished metastatic lesions in several animal systems (1-3) .
LAK cell therapy has also been successful in some advanced
cancer (most notably so in melanoma and renal cell carci-
noma), with complete or partial responses in 20-30% of the
patients . Recent studies have shown thatNK cells comprise
the major cell type that responds to IL-2 to generate LAK
cell activity (4) . Upon culture with 11,2, NK cells develop
high levels ofcytotoxic activity against a wide range of tumor
target cells . Many of these activated cells adhere to plastic,
allowing for the isolation and rapid expansion of highly en-
riched populations of cells with NKphenotype (5) . These
Abbreviations used in this paper . A-LAK, adherent, lymphokine-activated
killer cells ; AsGMI, asialo-GM1 ; LAK, lymphokine-activated killer cells ;
rhodamine, tetramethylrhodamine isothiocyanate ; st-LAK, standard lym-
phokine-activated killer cells.
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cells, termed adherent LAK (ALAK) cells, show a higher
potential of in vitro cytotoxicity (5) and are more effective
than unpurified LAK cells in therapy of lung and liver
metastases in a rat model (6) . Despite these promising results,
a better understanding of the mechanism(s) behind the in
vivo anti-cancer effect ofLAK andALAK cells is still wanted
with the aim of further increasing the frequency and dura-
bility of the anti-tumor responses .
The extent of accumulation of effector cells within, or in
the near vicinity of, malignant lesions might be decisive for
the efficacy of adoptive immunotherapy of cancer. Whilemuch
is known about adhesion molecules responsible for the in vivo
distribution and selective uptake in certain organs of other
effector cell types, mainly T cells, only scarce information
regardingLAK andALAK cells is published . However, char-
acterization of the in vivo migration LAK/A-LAK cells is
a prerequisite for further investigation of the molecular mech-
anisms determining LAK/A-LAK cell adhesion and migra-
tion to sites of infection or malignant disease.
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by analyzing the distribution ofinjected effector cells (7-14),
convincing evidence whetherLAK/ALAK cells actually mi-
grate to, and infiltrate malignant lesions in numbers sufficient
to eradicate tumors or tumormetastases is still missing. One
major limitation to interpretation has been the utilization
of radioisotopes for identification of theinjected cells. In ad-
dition to problems concerning reutilization of radiolabel
released by dead cells (15, 16), they may not be suitable for
precise detection of small proportions of the injected cells
accumulating in malignant lesions located in organs such as
lung, liver, and spleen, where considerable accumulation of
effector cells is reported to occureven in theabsence of tumors
(7, 8) . Furthermore, radiolabelsdo not easily permit discrimi-
nation between infiltration of malignant and normal tissue
within a specimen .
We therefore studied the in vivo distribution of A-LAK
cells labeled with the fluorescent dye rhodamine, in tumor
bearing animals . This method, previously used in lympho-
cyte traffic studies of Butcher et al . (17, 18), allows for pre-
cise identification of injected, fluorescent cells in frozen sec-
tions of various organs and makes it possible to determine
their exact relation to the malignant lesions.
Materials and Methods
Animalsand CellLines.
￿
Male C57BL/6 mice, 10-14 wk-of-age,
were used. The sublines F1 and F12H(1.4) of the B16 melanoma
(C57BL/6 origin) and the P815 mastocytoma (DBA origin) were
maintained in vitro in RPMI 1640 medium supplemented with
10% FCS, 2mM glutamine, 0.8 g/I streptomycin and 1.6 x 105
U/L penicillin, hereafter referred to as complete medium . Adherent
cells were detached by exposure to0.02% EDTA for 5-8 min and
washed three times in PBS . The cells were resuspended in RPMI
1640 to a final concentration of 10 x 105 per ml . Cell viability
wasalways >95% asjudged by trypan blue dye exclusion test. Pul-
monary metastases of B16-Fl melanoma cells were established by
tail vein injection of 2 x 105 cells in a volume of 0.2 ml . Liver
metastases were induced by left ventricular injection of 0.5 x 106
B16-F12H(1 .4) melanoma cells into 10-14wk oldmale C57BL/6 .
The 1316-1`1214(1.4) subline was established in our laboratory from
liver metastases arising from B16-Fl and induces a considerably
higher number of liver metastases than the B16 F-1 line after left
ventricular injection .
Preparation ofLAK andA-LAK Cells .
￿
StandardLAK (st-LAK)
cells were prepared as describedby Rosenstein et al . (19) . Briefly,
spleens were harvested and single-cell suspension was prepared in
RPMI 1640 . RBCs were lysed by incubation with ammonium
chloride-potassium buffer and the cells were thereafter washed two
times . Cells were transferred into T150 plastic flasks and cultured
for 3-5 d (37°C, 5% CO Z) in 50 ml of complete medium sup-
plemented with nonessential amino acids and 5 x 10 -5M2-ME
andhuman recombinant 11,2 (1000 U/ml - kindly provided by the
Cetus Corporation, Emeryville, CA and EuroCetus, Amsterdam,
the Netherlands) . The preparation ofA-LAK cells has been de-
scribed elsewhere (6) . Briefly, spleen cells suspensions were pre-
pared and incubated with 11,2 as described above. After 2-3 d of
incubation, nonadherent spleen cells were removed and the flasks
gently washed with prewarmed (37°C) complete medium to re-
move cells not firmly attached to the plastic . 50 ml fresh complete
medium, supplemented as described above, were addedandthe cells
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were cultured for an additional 2-3 d . After at total of 5 d of cul-
turing, cells were harvested after a short treatment with 0.02%
EDTA andwashed twice inRPMI 1640 before use. Routinely, the
A-LAK cells were phenotypically >95% large, granular lympho-
cytes, >98% asialo-GMt +, 60-95% NK1.1 but only 4-9% Lyt
2+ and <2% L3T4+, in agreementwith previous findings (4, 6) .
Labeling ofA-LAK Cells with Rhodamine andPKH26 .
￿
3-6 x
108 A-LAK cells were incubated with 15 Ag rhodamine (TRITC ;
Sigma Chemical Co., St . Louis, MO) in 50 ml RPMI 1640 (0.3
AA/ml) for 30 min at 37°C (this low dose of rhodamine does not
alter the proliferative properties or the cytotoxic capacity of the
A-LAK cells) . After labeling, cells were washed twice in RPMI
1640 and adjusted to 75 x 106 cells/ml . In selected experiments,
A-LAK cells were stained with PKH26 (Zynaxis Cell Science, Inc.,
Malvern, PA). Briefly, 5 x 107 pelleted A-LAK cells were
resuspended in 1 ml ofdiluent forPKH26 . Immediately thereafter,
1 ml of a 20 PM solution of PKH26 in diluent was added and
allowed to react with theA-LAK cells for2 min at room tempera-
ture . The cells were washed twice in RPMI 1640 containing 10%
fetal bovine serum. Fifteen millionA-LAK cells resuspended in 200
AlRPMI 1640 were injected into the lateral tail vein . Lungs were
removed 16 h after injection ofA-LAK cells and frozen sections
were prepared . To inhibit leakage of PKH26, one drop of
cyanocryolit (DuroSuper Glue, Loclite corp ., Cleveland, OH) was
used as mounting media for coverslips . After fluorescence pho-
tomicrographs were taken, the coverslips were removedby soaking
the slides in acetone for24-48h. The sections were counterstained
with Mayer's haematoxylin and microphotographs were made under
a light microscope.
Adoptive TransferofA-LAK Cells -IntravenousAdministration.
￿
On
day 3, 6, 9, or 12 of tumor growth, each mouse received 15 or
45 x 106 rhodamine labeled A-LAK cells i.v. and 20,000 U IL2
i.p . at 0and 8h. One or 16 h after injection, lungs were removed
and processed as described below .
Adoptive Transfer ofA-LAK Cells - Intraportal Administration.
￿
On
day 9 of tumor growth, each mouse received 15 x 106 rhodamine
labeled A-LAK cells intraportally . Mice were anesthetized with
Nembutal and the anterior abdominal wall was opened . A branch
of the portal vein system was identified and 200 Al RPMI 1640
containing 15 x 106 A-LAK cells were injected using a 30 gauge
needle. Bleeding was stopped by light compression . The abdominal
wall was closed with surgical clips. Mice were given i.p . injections
of 20.000 u of 11,2 every 8 h. One or 16 h after injection, livers
were removed and processed as described below.
FluorescentMicroscopy .
￿
One or 16h after injection of theA-LAK
cells, lungs were fixed in 4% formalin (installed via the trachea)
for 18 h and subsequently placed in 30% sucrose for additional
18h. Livers were fixed in4% formalin for 24 hand thereafter placed
in 30% sucrose for additional 18h. After fixation, the tissueswere
snap-frozen in n-Hexane at -70°C and 8 P.m cryo-sections were
made . Rhodamine or PKH26 labeledA-LAK cellswere identified
by use of a Zeiss Fluorescence Microscope with a HBO 200 w/4
mercury vapor luminatorand with filter combinations for rhoda-
mine (BP 546, FT 580 and LP 590) . Metastatic lesions were easily
identified by light microscopy due to thehigh content of melanin
produced by the melanoma cells .
Electron Microscopy.
￿
Lung lobes were fixed for microscopy 2.5%
glutaraldehyde in 0.05MNa cacodylate buffer, pH 7.2 . The fixa-
tive was installed into the bronchial tree until the lobes assumed
a shape corresponding to maximum inhalation . Specimens were
kept in aldehyde for 2 d and were treated with Os04, stained en
bloc, dehydrated and infiltrated with Agar 100 resin according to
routine procedures . Ultrathin sections were cut with a Reichert
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tron microscope .
Enumeration of Tumor Infiltrating A-LAK Cells.
￿
One and 16 h
after ix. injection of 15 x 106 rhodamine or PKH26 labeled
A-LAK cells, multiple sections (8 ftm) of lungs and livers were
made from animals bearing day 3, 6, 9, or 12-d-old B16-Fl lung
or 9-d-old B16-F12H(1.4) liver metastases (3 animals from each
group) . The number of infiltrating A-LAK cells in individual
metastatic lesions as well as the number ofA-LAK cells per sqmm
ofthe surrounding normal tissue were counted in animals bearing
6-12-d-old lung or 9-d-old B16-F12H(1.4) liver metastases. The area
ofthe metastases was measured and the average number ofA-LAK
cells/sqmm metastatic tissue was calculated . The very small number
oftumor cells within day 31ung metastases prevented precise quan-
tization of the area of the lesion (distinct nodules were seldom
formed) and therefore the term "infiltration" is misleading. Con-
sequently, tumors of a size less than 40 x 40,um were placed in
the center ofa square of this size and all of theA-LAK cells within
this area were counted . Therefore, the number ofA-LAK cells per
sq.mm of tumor and tumor associated tissue is presented as : the
number of A-LAK cells in the 40 x 40 um area/0.0016 mm .
Estimation of the A-LAK Cell:Tumor Cell Ratio in Day 9 Lung
andLiverMetastases. TheALAK cell:tumor cell ratio in individual
day 91ung and liver metastases 16 h after inoculation (i.v. and in-
traportally, respectively) of 15 x 106 rhodamine A-LAK cells was
estimated as follows : (area of metastases x 0.008/average volume
ofthe tumor cell)/number ofinfiltratingA-LAK cells, where 0.008
is the section thickness in mm . The average volume of one tumor
cell was determined from in vitro cultured B16 melanoma cells and
was found to be 2.03 x 10-6 mm' (average diameter - 15.7 P,m) .
More than 100 lung or liver metastases from 6 different animals
were analyzed .
Flow Cytometric Analysis.
￿
The following antibodies were used :
rabbit anti-asialo GMl serum (Wako Chemical Company, Dallas,
TX), mAB NK1 .1 (PK136, American Type Culture Collection),
fluorescein-conjugated rat mAB anti-Lyt-2 and rhodamine-
conjugated rat mAB L3T4 (Becton-Dickinson andCo., Sunnydale,
CA), fluorescein-conjugated swine anti-rabbit IgG and fluorescein-
conjugated goat anti-mouse IgG (F205 and F313, Dakopatts, Den-
mark) . Cells were harvested and resuspended at 5 x 105 per tube
in staining buffer (PBS, 2% AB serum) . After centrifugation, anti-
serum or mAB were added to the pellet and incubated 30 min at
4°C . The cells were washed twice and incubated with FITC-labeled
anti-IgG ofthe primary antibodies for an additional 30 min at 4°C .
After washing, cells were fixed in 1% paraformaldehyde. Flow cyto-
metric analysis were performed using a Profile flow cytometer with
logarithmic amplification (Coulter Electronics Limited, Luton, UK) .
Results
The Rhodamine Label.
￿
Immediately after incubation with
rhodamine, the ALAK cells are strongly fluorescent, but their
intensity declines rapidly over time, limiting the use of this
technique to about 20-24 h after labeling (17, 18) . It cannot
be excluded that binding of rhodamine to intracellular pro-
teins interferes with various cell functions, but upon labeling
with low doses of rhodamine, as used here (<0.5 ug/ml),
no changes in adherence, proliferation or cytolytic capacity
of the labeled A-LAK cells were detected (data not shown) .
Accumulation ofIntravenous Injected A-LAK Cells in Lung
Metastases.
￿
One hour after ix., injection ofrhodamine-labeled
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A-LAK cells into C57 BL/6 mice bearing experimental lung
metastases from the syngeneic B16 melanoma, most of the
injectedALAK cells were evenly distributed in the lung tissues
(Fig. 1, a and b) . At this time, there was no significant differ-
ence between the number ofALAKcells per sqmm of normal
and metastic tissue, with the exception of very small (day
3) tumors (Fig. 2) . In contrast, a significant increase (p <
0.001) in the numbers ofALAK cells infiltrating the lung
metastases was observed at 16 h after injection, where the
number of ALAK cells in 6-, 9-, and 12-d-old metastatic
tumor tissue rose to more than 500/sq.mm, clearly demon-
strating a time dependent redistribution ofALAK cells to-
wards the malignant tissue (Fig. 1, c and d, and Fig. 2) . Simul-
taneously, the ALAK cells gradually disappeared from the
surrounding normal lung tissue, where less than 100ALAK
cells per sqmm could be found at 16 h (Fig. 2) . This distri-
bution pattern was not restricted to the B16 melanoma model
of metastasis, since we observed similar levels of accumula-
tion ofALAK cells in lung metastases induced by eitherMCA
102 sarcoma or Lewis Lung carcinoma cells (data not shown) .
Infiltration ofLung Metastases by Various Cell Types.
￿
To com-
pare infiltration of lung metastases by different subpopula-
tions ofLAK cells and to investigate whether the accumula-
tion of rhodamine-labeled cells in the metastases might be
due to non-specific entrapment of cells (i .e ., whether other
cell types than LAK cells accumulate in the lung metastases)
rhodamine-labeled fresh splenocytes, st-LAK cells grown for
3 or 5 d (st-LAK-3 and -5 respectively), A-LAK cells grown
for 5 d, as well as P815 and B16-Fl tumor cells were injected
i.v. into animals bearing 12-d-old lung metastases. No up-
take offresh spleen cells, P815 or B16-Fl cells in the metastases
was seen 0-16 h after injection (Table 1) . Splenocytes were
rapidly cleared from the lung tissue and redistributed mainly
to the white pulp areas of the spleen . In contrast, st-LAK-3
cells were able to infiltrate the lung metastases . This infiltra-
tion was, however, less efficient than the infiltration by ALAK
and st-LAK-5 cells (Table 1) .
Comparison between Rhodamine andPKH26.
￿
To ensure that
the infiltration of the lung metastases by the A-LAK cells
was not attributable to some metabolic effect of the rhoda-
mine label on the A-LAK cells, in selected experiments we
employed the fluorescent dye PKH26, which binds mainly
to the cell membrane (20, 21), thus displaying distinct phys-
ical and binding characteristics as compared to rhodamine,
which binds mainly to intracellular proteins (17) . A similar
pattern ofinfiltration oflung metastases by ALAK cells was
observed using this dye (data not shown), indicating that these
fluorescent dyes did not influence the distribution pattern of
theA-LAK cells. Since the half-life of the PKH26 on labeled
cells is much longer than the half-life of rhodamine this new
dye might be very useful in long term studies where labeled
cells are to be followed by more than 16-24 h.
Fate of Rhodamine and PKH26 Released from Dead Cells.
Since accumulation ofrhodamine or PKH26 in the metastases
due to uptake, e.g ., by tumor infiltrating macrophages, of
dye released from dead or dying A-LAK cells could not be
ruled out, pre-killedA-LAK cells, labeled with either rhoda-
mine or PKH26, were injected i.v. into animals bearingFigure 1 .
￿
(a) Fluorescence micrograph of lung tissue one hour after ix. injection of 15 x 106 rhodamine labeled A-LAK cells. The A-LAK cells
are evenly distributed in the lung tissue and do not show any accumulation in the malignant tissue (x140). (b) Haematoxylin staining of the section
shown in (a) . Note metastatic nodules of melanin-producing B16 melanoma cells (arrows) . (c) Fluorescence micrograph of lung tissue 16 h after ix.
injection of 15 x 106 rbodamine labeled A-LAK cells, showing accumulation of A-LAK cells in metastatic nodules . Only a few A-LAK cells are now
present in the normal lung tissue (x60) . (d) Haematoxylin staining of the section shown in (c). Arrows indicate metastatic nodules.
9-d-old lung metastases. These pre-killed A-LAK cells were
cleared from the lungs within a few hours and no uptake
in the metastases ofdye or dye-containing cell-debris was seen
0-16 h after injection . These experiments clearly show that
neither rhodamine, norPKH26 accumulates non-specifically
in the metastases.
Analysis of Infiltrated Lung Metastases by Electron Micros-
copy. To further validate the accumulation of ALAK cells
in the metastases, lung sections were examined by electron
microscopy. Probable killer cells, i .e ., cells with typical LGL
morphology, were found in most metastases of mice, which
had received ALAK cells and were treated with IL-2 (Fig .
3) . No cells with LGL morphology were identified in
metastases from animals that were given 11,2 only. The
infiltrating A-LAK cells were located both in capillaries and
in various stages ofexit from the microvessels into the inter-
stitium of the metastases.
Accumulation ofA-LAK Cells in LiverMetastases .
￿
Injection
of A-LAK cells by the intravenous route into mice bearing
lung metastases can be regarded as regional delivery of the
A-LAK cells to the lung metastases, since all i.v. injected cells
initially reach the lungs. In contrast, to reach liver metastases,
ALAK cells must first migrate through the lung vasculature
and, for those cells reaching the liver via the portal vein, the
capillary bed of the intestinal tract must also be traversed .
We have previously reported that intea-arterial (left ventric-
ular) inoculation of tumor cells resulted in increased distri-
bution to the liverwhen compared to i.v. injection (22) . Fur-
thermore, sinceALAK cells are large, rigid and less deformable
than other lymphoid cells (23), it appears that the capillaries
ofthe lungs and the intestinal tract might be limiting factors
for the subsequent circulation of ix. injected cells towards
the liver. Indeed, in animals bearing day 9 liver metastases,
very few ALAK cells were seen in normal and metastatic
tissue after ix. injection (Fig . 4 a) . The mean number of
A-LAK cells in the normal liver tissue remained constantly
low (<40 cells/sqmm) one to 16 h after inoculation (Fig. 5) .
The number of i.v. injectedA-LAK cells infiltrating the liver
metastases rose slightly from <50 cells/sq mm at 1 h to ap-
proximately 100 cells/sqmm by 16 h after inoculation (Fig. 5) .
To test whether a more direct delivery of A-LAK cells to
the liver could enhance the uptake ofALAK cells into the
liver and improve infiltration of liver metastases, rhodamine-
labeled A-LAK cells were inoculated directly into the portal
system, thus by-passing the lungs and the intestinal tract .
By this route, more than five times as many cells were seen
in the normal liver tissue 1 h after injection compared to the
situation after i.v. injection (-200 and -40 per sq mm,
respectively - Fig. 4 b and Fig . 5) . By 16 h, the number of
A-LAK cells in the normal liver tissue decreased to -100/sq
mm, whereas the number ofALAK cells per sqmm tumor
tissue rose to >500 per sqmm (Fig. 4 c, Fig . 5), i .e ., more
than 5 times as many as seen after i.v. injection .
Ratio ofA-LAK Cells and Target Cells in IndividualMetastases.
482
￿
Accumulation of Adoptively Transferred A-LAK Cells in Murine Metastasesc
N U
x
Q
Q
w
0
E
z
800
600
400
200
0
Lung
Normal tissue
Hours after injection
Figure 2.
￿
Number ofA-LAKcells per sqmm normal or metastatic lung
tissue 1 and 16 h after i.v. injection of 15 x 106 rhodamine labeled A-LAK
cells. Animals bearing 3-d-old metastases (open circles), 6-d-old metastases
(black circles) . 9-d-oldmetastases (open squares) or 12-d-old metastases (black
squares) . Statistical analysis (by Students double tailed t test) : Number of
A-LAK cells in tumor tissue one hour after injection vs. 16 h after injec-
tion ; day-3 : NS, day 6 : p <0.03, day-9 and day-12 : p <0.001. Number
of A-LAK cells in normal tissue one hour after injection vs . 16 h after
injection; p <0.001 in all groups.
As shown in Table 2, the ratio betweenALAK cells and tumor
cells (called; E/T ratio) varied considerably among individual
metastases in both lungs and liver when a moderate number
(15 x 106) of ALAK cells was injected . The E/T ratio in
-35% of the lung metastases was between 1:1 and 1:5 . Less
than one A-LAK cell per five tumor cells was seen in the
remaining lung metastases, and some 3-5% of the lung
metastases were totally without infiltration, even though they
were often located near well-infiltrated lesions. Serial sections
of such nodules revealed that lack of infiltration was not re-
stricted to certain areas of the metastases, but rather included
the entire lesion . The noninfiltrated nodules were of the same
size (or even larger) than the infiltrated lesions and no necrosis
or infiltration by inflammatory cells were seen, i .e . it is un-
likely that these nodules represent regressed metastases .
In the liver, the E/T ratio was as high as 1:1 to 1:5 in
6% of the metastases following intraportal injection, i.e., the
infiltration ofliver metastases was less efficient than the infiltra-
tion of lung metastases. Metastases totally free of infiltration,
as seen in the lung, were not observed in the liver following
intraportal injection .
TheE/T ratio within most lung metastases could be sub-
stantially improved simply by injecting more effector cells .
Thus, forty-five million A-LAK cells injected i.v. raised the
number ofinfiltrating effector cells in lung metastases to more
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Table 1 .
￿
Infiltration of Lung Metastases by Diferent Cell Types
Splenocytes, fresh spleen cells ; st-LAK-3 and st-LAK-5, spleen cells cul-
tured in IL-2 for 3 and 5 days respectively ; A-LAK-5 cells, adherentLAK
cells cultured in IL-2 for 5 days (see Materials and Methods) ; B16, B16
Fl melanoma ; P815, a mastocytoma cell line .
t The number of cells infiltrating day 12 lung metastases was counted
16 hours after inoculation of 20 x 106 rhodamine labeled cells . Each
animal received i.p . injections of 50,000 U IL-2 at 0, 4, and 8 hours of
cell inoculation . 40-50 metastases were examined in each group .
S Significantly different from A-LAK-5 and st-LAK-5 by the student's
t test (p < 0.005) .
than 2,000/sq mm or an average E/T ratio -1:1 . In many
lesions, the number of infiltrating cells was even higher, the
A-LAK cells comprising an almost confluent layer (Fig. 6,
a and b) . In this situation, precise enumeration of infiltrating
A-LAK cells became impossible . Even when these high
numbers of ALAK cells were administrated, some 5% of
the metastases were still totally resistant to infiltration by
A-LAK cells (Fig. 6, c and d) .
Discussion
Many investigations have been directed towards elucidating
the mechanisms oflymphocyte-mediated cytotoxicity andmo-
tility in vitro (24, 25) . However, in vivo distribution of adop-
tively transferred LAK or A-LAK cells has only been dealt
with in a few papers . Some of these have demonstrated ac-
cumulation of a smallnumber of injected effector cells within
the area of malignant lesions (1, 10-13) while others have
suggested that the effector cells do not at all migrate towards
sites of tumor growth (14, 26) .
Using the fluorescent dyes rhodamine andPKH26, which
allow for detailed analysis on single-cell level, we hereunam-
biguously demonstrate that ALAK cells accumulate within
malignant tissue upon adoptive transfer. Infiltration of the
metastatic lesions was confirmed by electron microscopy,
clearly demonstrating ALAK cells in close contact with mela-
noma cells. Intra-lesional accumulation ofA-LAK cells was
not restricted to metastases of B16 melanoma origin but was
also seen in lung metastases of LewisLung carcinoma orMCA
102 sarcoma origin . The ability of spleen cells to accumulate
within metastases seemed in someway to depend on the time
Phenotype of the adoptively
No . of infiltrating transferred cells (%)
cells per sq.mm
Cell type" tumor tissue (SD)t NK1 .1 LYT-2 AsGM1
splenocytes <10 4 12 7
st-LAK-3 404 (187)5 29 31 44
st-LAK-5 637 (370) 50 52 91
A-LAK-5 611 (281) 89 7 92
B16 0 0 0 0
P815 0 0 0 0Figure3 .
￿
Lowpower electron micrograph ofsubpleural melanoma metastasis (x1800). A-LAK cells wereinjected 16 hbefore sacrifice. The identification
of A-LAK cells (asterisks) depended on the presence of specific granules in this or adjacent sections as seen at higher magnification . Melanoma cells
are recognized by their content of melanin .
Figure 4 .
￿
(a) Fluorescence micrograph of liver tissue 16 h after ix. injection of 15 x 106 rhodamine labeled A-LAK cells, showing a few A-LAK
cells infiltrating a metastatic nodule. Few A-LAK cells are present in the normal liver tissue (x140) . (b) Fluorescence micrograph of liver tissue 1 h
after intraportal injection of 15 x 106 rhodamine labeled A-LAK cells . The A-LAK cells are evenly distributed in the liver tissue, but do not show
any accumulation in the malignant tissue (x60). (c) Fluorescence micrograph of liver tissue 16 hours after intraportal injection of 15 x 106 rhodamine
labeled A-LAK cells, showing accumulation of A-LAK cells in a metastatic nodule . Numerous A-LAK cells are still present in the surrounding normal
liver tissue (x60) .
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Figure 5 .
￿
Number of A-LAK cells per square mm normal or day-9
metastatic liver tissue one and 16 h after ix. (black circles) or intraportal
(open circles) injection of 15 x 106 rhodamine labeled A-LAK cells .
Statistical analysis (by Student's double tailed t-test) : Number of A-LAK
cells in tumor tissue one hour vs. 16 h after i .v. injection p <0.01; after
intraportal injection : p <0.001 . Number ofALAK cells in normal tissue
1 h vs . 16 h after i .v. injection : p <0.01; after intraportal injection : p <0.001 .
of incubation with IIT2 . Fresh, unactivated spleen cells did
not infiltrate the metastases at all, whereas both ALAK cells
and st-LAK cells, grown in IL2 for 5 d, infiltrated lung
metastases better than LAK cells cultured in IL2 for only
3 d . After 5 d in culture, NK (ALAK cells) and T cells (st-
LAK-5 cells) infiltrate the metastases equally well suggesting
that expression ofNKU and Lyt2 is not crucial for infiltra-
tion . On the other hand, expression ofthe asialo-GM1 gan-
Table 2 .
￿
Variation in A-LAK cell:tumor cell ratio among
individual lung and liver metastases
1:1-1:5
1:5-1:10
1:10-1 :15
1:15-1 :100
No infiltration
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% of metastases#
The tumor cell to A-LAK cell ratio in individual day 9 lung and liver
metastases 16 hours after inoculation of 15 x 106 rhodamine A-LAK
cells was estimated as described in Materials and Methods .
t Lung metastases were induced by i.v . injection of 2 x 10 5 B16-Fl
melanoma cells . Liver metastases were induced by intraportal injection
of 2 x 105 B16-F12H(1 .4) melanoma cells .
glioside seems to correlate with the infiltrative potential of
the LAK cells indicating a role ofthis structure in the migra-
tion process (27, 28) . However, whereas no clear evidence
exists concerning the therapeutical effect of these two cell
subpopulations in the murine system, Schwartz et al . (3) has
shown, that 11LAK cell therapy in a rat system is superior
to st-LAK cells .
While substantial infiltration of lung metastases was seen
after i.v. injection, significant infiltration of liver metastases
was seen only following intraportal injection of the ALAK
cells. Tumor infiltrating lymphocytes as well as inflamma-
tory cells are thought to circulate in the blood until they reach
their target tissues. If this was the case forALAK cells too,
the degree of infiltration ofliver metastases would be expected
to be similar regardless of the route of administration. Since
the accumulation ofALAK cells in the liver metastases was
much higher after local (i.e., intraportal) administration than
after i.v . injection, it seems more likely that at least part of
the tumor infiltrating A-LAK cells redistribute within the
organ, from normal liver tissue into metastases. The low
number ofALAK cells reaching the liver after i.v. injection
could be due to the pronounced rigidity ofALAK cells (23),
i .e., theALAK cells might simply become stuck in the lung
capillaries . Sequestration of ALAK cells in the lung capil-
laries might also be mediated by cell surface receptors as sug-
gested by Maghazachi et al. (26, 29), who found that prein-
cubation ofA-LAK cells with carbohydrates (e.g., mannose)
resulted in redistribution ofA-LAK cells from the lungs to
the liver. Thus, augmented uptake of A-LAK cells into the
liver and higher efficacy in treatment of liver metastases might
be obtained either by modulation ofhoming receptors orby
injecting the ALAK cells directly into the portal vein (or
into the hepatic artery for tumors nourished mainly by ar-
terial blood) . This is supported by Lafreniere and Rosenberg
(30), who found intraportal administration of LAK cells
significantly more effective in therapy ofliver sarcoma(MCA
105) metastases than i.v. administration of the same cells.
The mechanisms responsible for the in vivo tumoricidal
effect ofLAK and ALAK cells remain rather obscure, but
several potential possibilities exist : (a) ALAK cells may in-
teract directly with and lyse tumor cells . (b) A-LAK cells in
metastatic lesions may release cytokines such as tumor necrosis
factor that could mediate tumor cell damage and/or microvas-
cular coagulopathy and hemorrhagic necrosis . (c) ALAK cells
may damage or activate tumor microvasculature and lead to
extravasation ofother effector cells or cytolytic molecules with
resultant hemorrhagic necrosis . It is not possible yet to de-
termine which lytic mechanism plays the predominant role
in vivo, but ifLAK andALAK cell-mediated killing of tumor
cells in vivo requires direct contact between the killer cells
and the tumor targets, as is the case in vitro, then the ratio
between killer cells and tumor targets within the malignant
lesions becomes a critical factor for the efficacy of the an-
titumor effect, especially if the LAK or ALAK cells are not
capable ofunlimited recycling from tumor cell to tumor cell
(31) . After injection of a moderate number of A-LAK cells
(15 x 106), the ratio between A-LAK cells and tumor cells
varied considerably among individual metastases in both lungs
Lungs Liver
37.8 6 .4
44.9 28 .6
7 .1 22 .2
6.1 42 .8
4.1 0Figure 6 .
￿
Fluorescent micrographs (Fig. 6, a and c) oflung tissue 16 h after i .v. injection of 45 x 106 rhodamine-labeled A-LAK cells . The majority
of the lung metastases are highly infiltrated (Fig. 6, a and c, single-arrows), but few of the metastases remain free ofinfiltration (Fig . 6 c, double-arrow) .
Fig. 6 b and d show haematoxylin staining of the sections shown in Fig . 6 a and c (x60) .
and liver (Table 1) being as high as 1:1-5 in only 35-40%
of the lung metastases. Thus, it is of interest that adoptive
transfer of 15 x 106 A-LAK cells together with Ilr2, re-
duced the number of B16 melanoma lung metastases by
-40% (data not shown), indicating that at least a 1:5 ratio
ofALAK cells and tumor cells was needed to induce regres-
sion of a tumor nodule. After injection of higher numbers
of A-LAK cells (-45 x 106), the vast majority of lung
metastases became highly infiltrated (>2000 cells/sq mm or
an average E/T ratio -1:1) suggesting a dose dependent
infiltration of the metastases. Interestingly, a few (4-5%) of
the lesions, often those located around major vessels, remained
totally devoid of infiltrating A-LAK cells even though they
were often surrounded by highly infiltrated lesions . The ex-
istence of such noninfiltrated lesions, which are perhaps due
to heterogeneity in vascular access (32, 33), might in part
explain why LAK or A-LAK cell therapy, although capable
ofan 80-95% numerical reduction of metastases, seldom re-
sult in complete eradication of tumor burden (1-3) .
In conclusion, the present communication demonstrates
the novel finding that adoptively transferred LAK cells ac-
cumulate within lung and liver metastases upon a proper route
ofinjection . Our observation provides an important basis and
support both recent and future studies dealing with themo-
lecular effector-mechanisms behind LAK and ALAK cell-
mediated cytotoxicity, because further in vivo analysis ofthose
molecules (e.g., pore-forming cytolysin) and enzymes (e.g., pro-
teases), which have been shown to be involved in cell-mediated
lysis in vitro, would have no direct relevance if the effector
cells could not bring themselves in close contact with the
target cells.Due to the selective accumulation ofA-LAK cells
in malignant tissue compared to normal tissue, these studies
further indicate that A-LAK cells, in addition to their direct
or indirect cytolytic effector mechanisms, should also consti-
tute a vehicleby which anti-tumor drugs, attached toALAK
cells, can be selectively delivered to established micrometastatic
deposits .
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